Emergent BioSolutions makes the only FDA-approved anthrax vaccine.

Updates from The Motley Fool

Latest updates on Emergent BioSolutions from Fool.com.
Get Ready for the Bounce

"Don't catch a falling knife," as the old saw commands. (Pardon my mixing cutlery metaphors.) The...

Biotech Post-Holiday Regifting

Regifting is a social faux pas -- especially if you're caught -- but in the biotech industry, it'...

The Highest-Rated Biotech Stocks

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS...

Stock Performance

View Interactive EBS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Emergent BioSolutions.
Current Price: $26.27
Prev Close: $26.29
Open: $26.29
Bid: $23.29
Ask: $31.47
Day's Range: $25.96 - $26.80
52wk Range: $24.47 - $44.38
Volume: 282,484
Avg Vol 415,140
Market Cap: $1B
P/E (ttm): 26.83
EPS (ttm): $0.98
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Emergent BioSolutions.
CAPS Rating 4 out of 5
482 Outperform
17 Underperform
CAPS All Stars
86 Outperform
4 Underperform

How do you think Emergent BioSolutions will perform against the market?

You pick for Emergent BioSolutions is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Daniel J. Abdun-Nabi, CEO

79% Approve

Based on 64 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Emergent BioSolutions.

Emergent BioSolutions makes the only FDA-approved anthrax vaccine.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers